Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group has sued the U.

Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's weight-loss and diabetes treatments Wegovy and Ozempic from its shortage list,